Chong Kun Dang Pharmaceutical (185750) — Cash Flow Reinvestment Rate
Chong Kun Dang Pharmaceutical (185750) has a Cash Flow Reinvestment Rate of 7.60x as of March 2026, reinvesting ₩93.65 Billion (capex ₩74.34 Billion plus investments ₩19.31 Billion) from operating cash flow of ₩12.32 Billion. Check 185750 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Chong Kun Dang Pharmaceutical Cash Flow Reinvestment Rate (2016–2025)
Historical reinvestment intensity for Chong Kun Dang Pharmaceutical across 10 annual periods. Explore investment intensity of Chong Kun Dang Pharmaceutical to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Chong Kun Dang Pharmaceutical (2016–2025)
Year-by-year capital reinvestment analysis for Chong Kun Dang Pharmaceutical. For live market cap and broader valuation context, see 185750 company net worth.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 3.65x | ₩245.91 Billion | ₩67.36 Billion | ₩179.13 Billion | ▲ +73.4% |
| 2024 | 2.11x | ₩135.37 Billion | ₩64.29 Billion | ₩66.10 Billion | ▲ +179.0% |
| 2023 | 0.75x | ₩240.12 Billion | ₩318.16 Billion | ₩68.81 Billion | ▼ -11.4% |
| 2022 | 0.85x | ₩57.70 Billion | ₩67.73 Billion | ₩44.90 Billion | ▼ -87.4% |
| 2021 | 6.79x | ₩87.57 Billion | ₩12.90 Billion | ₩48.24 Billion | ▲ +1078.5% |
| 2020 | 0.58x | ₩60.08 Billion | ₩104.32 Billion | ₩32.64 Billion | ▲ +20.0% |
| 2019 | 0.48x | ₩37.09 Billion | ₩77.29 Billion | ₩21.84 Billion | ▼ -27.3% |
| 2018 | 0.66x | ₩28.12 Billion | ₩42.63 Billion | ₩21.92 Billion | ▲ +134.3% |
| 2017 | 0.28x | ₩23.00 Billion | ₩81.67 Billion | ₩19.79 Billion | ▼ -80.4% |
| 2016 | 1.43x | ₩82.84 Billion | ₩57.79 Billion | ₩39.44 Billion | — |